Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer

Arjun Menta; Tamer M. Fouad; Anthony Lucci; Huong Le-Petross; Michael C. Stauder; Wendy A. Woodward; Naoto T. Ueno; Bora Lim

doi:10.1016/j.suc.2018.03.009

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer

Arjun Menta, Tamer M. Fouad, Anthony Lucci, Huong Le-Petross, Michael C. Stauder, Wendy A. Woodward, Naoto T. Ueno, Bora Lim

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC.

Original language	English (US)
Pages (from-to)	787-800
Number of pages	14
Journal	Surgical Clinics of North America
Volume	98
Issue number	4
DOIs	https://doi.org/10.1016/j.suc.2018.03.009
State	Published - Aug 2018

Keywords

Breast changes
Clinical trials
Inflammatory breast cancer
Trimodality care

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.suc.2018.03.009

Cite this

@article{5c81ce3297f84e068720d9d4f0c6bd02,

title = "Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer",

abstract = "Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC.",

keywords = "Breast changes, Clinical trials, Inflammatory breast cancer, Trimodality care",

author = "Arjun Menta and Fouad, {Tamer M.} and Anthony Lucci and Huong Le-Petross and Stauder, {Michael C.} and Woodward, {Wendy A.} and Ueno, {Naoto T.} and Bora Lim",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = aug,

doi = "10.1016/j.suc.2018.03.009",

language = "English (US)",

volume = "98",

pages = "787--800",

journal = "Surgical Clinics of North America",

issn = "0039-6109",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Inflammatory Breast Cancer

T2 - What to Know About This Unique, Aggressive Breast Cancer

AU - Menta, Arjun

AU - Fouad, Tamer M.

AU - Lucci, Anthony

AU - Le-Petross, Huong

AU - Stauder, Michael C.

AU - Woodward, Wendy A.

AU - Ueno, Naoto T.

AU - Lim, Bora

PY - 2018/8

Y1 - 2018/8

N2 - Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC.

AB - Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC.

KW - Breast changes

KW - Clinical trials

KW - Inflammatory breast cancer

KW - Trimodality care

UR - http://www.scopus.com/inward/record.url?scp=85047338063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047338063&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2018.03.009

DO - 10.1016/j.suc.2018.03.009

M3 - Review article

C2 - 30005774

AN - SCOPUS:85047338063

SN - 0039-6109

VL - 98

SP - 787

EP - 800

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

IS - 4

ER -

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this